Inventor
DEVENPORT MARTIN
US12 patents
⚠️ This page may combine multiple inventors who share the name “DEVENPORT MARTIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ONCOC4 INC
7 patentsUS11261233B2Mar 1, 2022
CD80 and CD86 binding protein compositions and uses thereof
ONCOC4 INC6 citations83
US12227557B2Feb 18, 2025
CD80 and CD86 binding protein compositions and uses thereof
ONCOC4 INC2 citations72
US12473362B2Nov 18, 2025
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
ONCOC4 INC0 citations61
US11629188B2Apr 18, 2023
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
ONCOC4 INC0 citations61
US12441780B2Oct 14, 2025
CD80 and CD86 binding protein compositions and uses thereof
ONCOC4 INC0 citations60
US12129299B2Oct 29, 2024
Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
ONCOC4 INC0 citations60
US12286485B2Apr 29, 2025
Anti-CD24 compositions and uses thereof
ONCOC4 INC0 citations50
ONCOIMMUNE INC
5 patentsUS10618960B2Apr 14, 2020
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
ONCOIMMUNE INC12 citations84
US11911441B2Feb 27, 2024
Methods of use of CD24 for the prevention and treatment of leukemia relapse
ONCOIMMUNE INC0 citations61
US11571461B2Feb 7, 2023
Methods of use of soluble CD24 for treating lupus nephritis
ONCOIMMUNE INC0 citations61
US11547741B2Jan 10, 2023
Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
ONCOIMMUNE INC0 citations60
US10799558B2Oct 13, 2020
Use of CD24 proteins for treating leptin-deficient conditions
ONCOIMMUNE INC0 citations51